Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive
Michael Ewers, John P. A. Ioannidis, Nikolaus Plesnila
Abstract
•Challenges of rapid COVID-19 drug development risk to compromise good scientific practice•Access to patient-level data especially urgent to address risks of protocol violations and rapid reviews.•Open access to data enables transparency, secondary analyses, and meta-analyses.•Politicization of scientific reports will be reduced by cross-checking and multilateral analyses.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicClinical trialMedicineVirologyOutbreakPathologyDiseaseInfectious disease (medical specialty)Healthcare cost, quality, practicesEthics in Clinical ResearchBiomedical Ethics and Regulation